Compare · APRE vs NVS
APRE vs NVS
Side-by-side comparison of Aprea Therapeutics Inc. (APRE) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APRE and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.18B, about 28918.5x APRE ($9.8M).
- Over the past year, APRE is down 49.0% and NVS is up 30.5% - NVS leads by 79.5 points.
- APRE has been more active in the news (11 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 5 for APRE).
- Company
- Aprea Therapeutics Inc.
- Novartis AG
- Price
- $0.85+8.02%
- $153.35+3.02%
- Market cap
- $9.8M
- $284.18B
- 1M return
- -8.20%
- +0.99%
- 1Y return
- -49.05%
- +30.46%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 11
- 1
- Recent ratings
- 5
- 25
Aprea Therapeutics Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest APRE
- Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
- Director Grissinger Michael was granted 3,135 shares, increasing direct ownership by 109% to 6,024 units (SEC Form 4)
- Director Gruia Gabriela was granted 3,135 shares, increasing direct ownership by 300% to 4,180 units (SEC Form 4)
- Director Peters Richard was granted 3,135 shares, increasing direct ownership by 101% to 6,254 units (SEC Form 4)
- Director Henneman John B Iii was granted 3,135 shares, increasing direct ownership by 31% to 13,364 units (SEC Form 4)
- Director Bizzari Jean-Pierre was granted 3,135 shares, increasing direct ownership by 300% to 4,180 units (SEC Form 4)
- Director Duey Marc was granted 3,135 shares, increasing direct ownership by 1% to 259,290 units (SEC Form 4)
- Director Pamukcu Rifat was granted 3,135 shares, increasing direct ownership by 58% to 8,581 units (SEC Form 4)
- Director Seizinger Bernd R. was granted 3,135 shares, increasing direct ownership by 7% to 48,910 units (SEC Form 4)
- Aprea Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG